银杏叶提取物EGb761对慢性乙型肝炎患者肝纤维化的影响
http://www.100md.com
梁 斌, 张春清, 任万华, 主余华
银杏叶提取物;慢性乙型肝炎;肝纤维化,梁斌,张春清,任万华,主余华,梁斌,通讯作者:,电话:,收稿日期:,接受日期:,Effectofginkobilobaextractonliverfibrosisinpatientswith
参见附件(1kb)。
梁斌, 张春清, 任万华, 主余华, 山东大学山东省立医院消化内科 山东省济南市 250021
梁斌, 硕士研究生, 主要从事消化系疾病的研究.山东省科委优秀中青年科学家基金, No. 03BS016
通讯作者: 主余华, 250021, 山东省济南市, 山东大学山东省立医院肝病中心. zyh6698@yahoo.com.cn
电话: 0531-85186450
收稿日期: 2006-11-30 接受日期: 2006-12-27
Effect of ginko biloba extract on liver fibrosis in patients with chronic hepatitis B
Guo-Bao Tian, Zheng Zeng, Hai-Ying Lu, Jian-Jun Cui, Di Tian
Bin Liang, Chun-Qing Zhang, Wan-Hua Ren, Yu-Hua Zhu, Department of Gastroenterology, Shandong Provincial Hospital, Shandong University, Ji’nan 250021, Shandong Province, China
Supported by the Foundation of Shandong Provincial Science and Technology Committee for the Excellent Young and Middle-aged Scientists, No. 03BS016
Correspondence to: Yu-Hua Zhu, Center of Hepatopathy, Shandong Provincial Hospital, Shandong University, Ji’nan 250021, Shandong Province, China. zyh6698@yahoo.com.cn
Received: 2006-11-30 Accepted: 2006-12-27
AbstractAIM:To evaluate the efficacy of ginko biloba extract (EGb761) in the treatment of patients with liver fibrosis caused by chronic hepatitis B.
METHODS: Sixty patients with chronic hepatitis B were randomly divided into EGb761 treatment group (n = 32) and control group (n = 28). Liver functions, serum type Ⅲ precollagen (PCⅢ), type Ⅳ collagen (CⅣ), hyaluronic acid (HA), laminin (LN), platelet activating factor (PAF), endothelin-1 (ET-1) and transforming growth factor-β1 (TGF-β1) levels were measured before and after treatment. Twenty-six cases in EGb group and 21 cases in control group received liver biopsy before and after treatment, and the pathological changes of liver tissues were detected by HE, Masson and Gordon-Sweet staining.
RESULTS: After treatment, the indexes of liver function showed obvious improvement in both groups, and there were no significant difference between two groups. The value of prothrombin time (13.2 ± 2.1 s vs 15.2 ± 3.4 s, P < 0.05), the levels of serum alanine aminotransferase (621.8 ± 271.7 nkat/L vs 1258.6 ± 308.4 nkat/L, P < 0.05), total bilirubin (17.1 ± 9.5 μmol/L vs 39.3 ± 21.2 μmol/L, P < 0.01), PCⅢ (168 ± 48 μg/L vs 307 ± 93 μg/L, P < 0.05), CⅣ (102 ± 35 μg/L vs 191 ± 35 μg/L, P < 0.01), HA (94 ± 39 μg/L vs 178 ± 57 μg/L, P < 0.05), LN (101 ± 31 μg/L vs 193 ± 21 μg/L, P < 0.05), PAF (7.62 ± 6.54 µg/L vs 13.23 ± 9.79 µg/L, P < 0.05), ET-1 (47.61 ± 15.34 µg/L vs 68.13 ± 21.71 µg/L, P < 0.01) and TGF-β1 (17.61 ± 5.06 µg/L vs 58.43 ± 11.04 µg/L, P < 0.05) were significantly decreased after treatment than those before treatment, while the level of albumin was markedly increased (38.2 ± 5.9 g/L vs 34.9 ± 4.4 g/L, P < 0.05). There were also notable differences between EGb761 and control group after treatment in the levels of TGF-β1 (17.61 ± 5.06 µg/L vs 61.17 ± 11.45 µg/L, P < 0 ......
梁斌, 张春清, 任万华, 主余华, 山东大学山东省立医院消化内科 山东省济南市 250021
梁斌, 硕士研究生, 主要从事消化系疾病的研究.山东省科委优秀中青年科学家基金, No. 03BS016
通讯作者: 主余华, 250021, 山东省济南市, 山东大学山东省立医院肝病中心. zyh6698@yahoo.com.cn
电话: 0531-85186450
收稿日期: 2006-11-30 接受日期: 2006-12-27
Effect of ginko biloba extract on liver fibrosis in patients with chronic hepatitis B
Guo-Bao Tian, Zheng Zeng, Hai-Ying Lu, Jian-Jun Cui, Di Tian
Bin Liang, Chun-Qing Zhang, Wan-Hua Ren, Yu-Hua Zhu, Department of Gastroenterology, Shandong Provincial Hospital, Shandong University, Ji’nan 250021, Shandong Province, China
Supported by the Foundation of Shandong Provincial Science and Technology Committee for the Excellent Young and Middle-aged Scientists, No. 03BS016
Correspondence to: Yu-Hua Zhu, Center of Hepatopathy, Shandong Provincial Hospital, Shandong University, Ji’nan 250021, Shandong Province, China. zyh6698@yahoo.com.cn
Received: 2006-11-30 Accepted: 2006-12-27
AbstractAIM:To evaluate the efficacy of ginko biloba extract (EGb761) in the treatment of patients with liver fibrosis caused by chronic hepatitis B.
METHODS: Sixty patients with chronic hepatitis B were randomly divided into EGb761 treatment group (n = 32) and control group (n = 28). Liver functions, serum type Ⅲ precollagen (PCⅢ), type Ⅳ collagen (CⅣ), hyaluronic acid (HA), laminin (LN), platelet activating factor (PAF), endothelin-1 (ET-1) and transforming growth factor-β1 (TGF-β1) levels were measured before and after treatment. Twenty-six cases in EGb group and 21 cases in control group received liver biopsy before and after treatment, and the pathological changes of liver tissues were detected by HE, Masson and Gordon-Sweet staining.
RESULTS: After treatment, the indexes of liver function showed obvious improvement in both groups, and there were no significant difference between two groups. The value of prothrombin time (13.2 ± 2.1 s vs 15.2 ± 3.4 s, P < 0.05), the levels of serum alanine aminotransferase (621.8 ± 271.7 nkat/L vs 1258.6 ± 308.4 nkat/L, P < 0.05), total bilirubin (17.1 ± 9.5 μmol/L vs 39.3 ± 21.2 μmol/L, P < 0.01), PCⅢ (168 ± 48 μg/L vs 307 ± 93 μg/L, P < 0.05), CⅣ (102 ± 35 μg/L vs 191 ± 35 μg/L, P < 0.01), HA (94 ± 39 μg/L vs 178 ± 57 μg/L, P < 0.05), LN (101 ± 31 μg/L vs 193 ± 21 μg/L, P < 0.05), PAF (7.62 ± 6.54 µg/L vs 13.23 ± 9.79 µg/L, P < 0.05), ET-1 (47.61 ± 15.34 µg/L vs 68.13 ± 21.71 µg/L, P < 0.01) and TGF-β1 (17.61 ± 5.06 µg/L vs 58.43 ± 11.04 µg/L, P < 0.05) were significantly decreased after treatment than those before treatment, while the level of albumin was markedly increased (38.2 ± 5.9 g/L vs 34.9 ± 4.4 g/L, P < 0.05). There were also notable differences between EGb761 and control group after treatment in the levels of TGF-β1 (17.61 ± 5.06 µg/L vs 61.17 ± 11.45 µg/L, P < 0 ......
您现在查看是摘要介绍页，详见PDF附件(1kb)。